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Abstract
Background Changes in well-being of patients with multiple myeloma (MM) before and after diagnosis have not been 
quantified.
Aims Explore the use of secondary data to examine the changes in the well-being of older patients with MM.
Methods We used the Health and Retirement Study (HRS), linked to Medicare claims to identify older MM patients. We 
compared patient-reported measures (PRM), including physical impairment, sensory impairment, and patient experience 
(significant pain, self-rated health, depression) in the interviews before and after MM diagnosis using McNemar’s test. We 
propensity-matched each MM patient to five HRS participants without MM diagnosis based on baseline characteristics. We 
compared the change in PRM between the MM patients and their matches.
Results We identified 92 HRS patients with MM diagnosis (mean age = 74.6, SD = 8.4). Among the surviving patients, 
there was a decline in well-being across most measures, including ADL difficulty (23% to 40%, p value = 0.016), poor or fair 
self-rated health (38% to 61%, p value = 0.004), and depression (15% to 30%, p value = 0.021). Surviving patients reported 
worse health than participants without MM across most measures, including ADL difficulty (40% vs. 27%, p value = 0.04), 
significant pain (38% vs. 22%, p value = 0.01), and depression (29% vs. 11%, p value = 0.003).
Discussion Secondary data were used to identify patients with MM diagnosis, and examine changes across multiple measures 
of well-being. MM diagnosis negatively affects several aspects of patients’ well-being, and these declines are larger than 
those experienced by similar participants without MM.
Conclusion The results of this study are valuable addition to understanding the experience of patients with MM, despite 
several data limitations.
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Introduction
Multiple myeloma is a rare disease, affecting approxi-
mately 7 out of 100,000 persons in the United States 
each year. Multiple myeloma disproportionately affects 
older patients, with a median age at diagnosis being over 
70 years old [1]. While new treatments are increasing the 
survival time [2], we know less about the quality of life 
of older persons who are more susceptible to treatment 
related adverse events. Older patients are concerned not 
only with survival time, but also with symptom manage-
ment, maintaining independence, and how their well-being 
will be affected by the disease and treatments [3]. Previous 
studies have shown that patients with multiple myeloma 
experience higher symptom burden and lower quality of 
life compared to the general population [4, 5], but these 
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studies did not focused on older patients specifically. Over-
all, there is a consensus that older patients with multiple 
myeloma could benefit from a geriatric assessment before 
and during treatment [3, 6, 7]. However, to our knowledge, 
there have been no studies that formally quantify patient-
reported measures in older multiple myeloma patients 
before and after the diagnosis, or studies comparing the 
changes in well-being to older adults experiencing the nor-
mal ageing process.
As with any rare disease, it can be difficult to recruit large 
numbers of multiple myeloma patients for research stud-
ies due to the low prevalence of the disease, which makes 
recruiting large numbers of patients resource intensive. One 
potential source of data for studies of rare diseases is second-
ary data, including large observational studies and adminis-
trative data. In this study we explore studying the well-being 
of older multiple myeloma patients using Medicare claims 
data, and Health and Retirement Study (HRS), an ongoing 
longitudinal study started in 1992. The use of this longitu-
dinal cohort has several advantages. First, due to length of 
the study period, enough cases accrue over time, creating a 
feasible study sample. Second, HRS is a detailed study with 
data on a variety of health status measures that are of interest 
for older patients. Third, since HRS is a longitudinal study, 
each surviving participant is interviewed every 2 years, 
meaning that the measures of interest are observed before 
and after the diagnosis. Fourth, we can compare changes 
in the health status measures in HRS participants without 
multiple myeloma, for whom we have the same health status 
measures over the same period of time.
The use of HRS data that were not collected for the pur-
pose of learning about well-being of multiple myeloma 
patients imposes limits on questions that can be answered. 
For example, since we do not have the information on what 
treatment the patients receive, we can not determine if 
well-being changes are due to the disease or its treatment. 
In addition, because the HRS interviews are biennial, the 
time between multiple myeloma diagnosis and report of 
health status measures varies between 0 days and 2 years. 
However, HRS data also make it possible to address issues 
that would be difficult in a primary data collection study. 
It makes it possible to collect data on prediagnosis health 
status rather than retrospective reports. In addition, we can 
compare changes in health to population-representative sub-
jects without multiple myeloma.
We conducted this study examining changes before and 
after multiple myeloma diagnosis with three specific goals: 
(1) assessing feasibility of using claims data to identify and 
study patients with multiple myeloma; (2) assessing the 
change in patient-reported measures before and after diag-
nosis; (3) comparing the change in patient-reported meas-




The Health and Retirement Study (HRS) was designed to 
examine changes in health and wealth as people age [8]. It 
is an ongoing nationally representative longitudinal study 
of participants age 50 and older. The study started in 1992 
and follow up surveys are administered every 2 years. If a 
participant is not able to complete an interview, the inter-
view is conducted with a proxy respondent.
We examined participants who had a diagnosis of mul-
tiple myeloma while enrolled in the HRS, ascertained by 
linking the HRS survey data to Medicare claims. A par-
ticipant was identified as having a diagnosis of multiple 
myeloma if he or she had two or more Medicare claims 
with ICD9 code 203.0. While we required two claims to 
confirm the diagnosis of multiple myeloma, the date of 
diagnosis was set to the date of first claim.
Out of 28,927 HRS participants age 65 or older at any 
point between 1992 and 2015, 26,044 (90.0%) agreed to 
have their HRS surveys linked to the Medicare claims. We 
identified 126 participants who had two or more claims 
with multiple myeloma. Since we wanted to ensure that 
the first claim observed in our files was indeed the first 
diagnosis of multiple myeloma, we excluded 21 (16.7%) 
participants if they were not enrolled continuously in 
fee-for-service Medicare for 6 months prior to the first 
observed claim with multiple myeloma diagnosis. Of the 
remaining 105 multiple myeloma patients, 13 (12.4%) did 
not complete a HRS interview within 3 years before a mul-
tiple myeloma diagnosis and were, therefore, excluded. 
This resulted in a sample of 92 multiple myeloma patients 
included in the study.
Measures
All baseline characteristics of study participants were 
taken from the last HRS interview before a diagnosis of 
multiple myeloma. Those included participant character-
istics (age, gender, race, marital status, education, wealth, 
comorbidities, and health behaviors), and patient-reported 
measures of interest.
We considered nine patient-reported measures that 
cover a range of well-being for multiple myeloma patients, 
and are part of geriatric assessment of older patients [9, 
10]. The included measures cover the domains that mat-
ter most to patients: functioning, sensory impairment, and 
general well-being. While the nine measures do not con-
stitute together a validated questionnaire, each one of the 
measures has been validated or used in prior research of 
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patients’ well-being. We include below the exact text of 
the survey question for each measure, and the justifica-
tion for the new coding, when the questions were not used 
in the original form. Additionally, HRS website includes 
detailed documentation guides for all the measures used in 
this study [8]. Four measures describe limitations in physi-
cal functioning: difficulty in any Activities of Daily Living 
(ADL), difficulty in any Instrumental Activities of Daily 
Living (IADL), difficulty walking several blocks, and dif-
ficulty climbing one flight of stairs. ADL and IADL meas-
ures are standardized measures of assessing function in 
older adults in both clinical and research setting [11, 12]. 
Difficulty in any functional measure was assessed in the 
HRS by asking, “Because of a health or memory problem 
do you have any difficulty with [activity]?”. There were 
six ADLs (bathing, eating, walking across the room, trans-
ferring to and from bed, using toilet, and dressing), and 
five IADLs (using a phone, preparing hot meals, grocery 
shopping, managing financing, managing medications) 
included in the assessment. Next, two sensory impairment 
measures were included: vision and hearing impairment. 
Each of the two sensory impairments were assessed by 
asking, “Is your [hearing/eyesight] excellent, very good, 
good, fair, or poor using a [hearing aid/glasses or cor-
rective lenses] as usual?”. Finally, three additional meas-
ures of general well-being were considered: experience 
of significant pain, self-rated health, and self-reported 
symptoms of depression. The presence of significant pain 
was determined using two questions. First, subjects were 
asked, “Are you often troubled with pain?”. Subjects who 
responded “Yes” were then asked, “How bad is the pain 
most of the time: mild, moderate or severe?” Subjects who 
responded “moderate” or “severe” were classified as expe-
riencing significant pain. This classification of significant 
pain has been applied in previous studies [13, 14], because 
it reflects the American Geriatrics Society Guidelines for 
the Pharmacologic Management of Persistent Pain in 
Older Adults and the National Comprehensive Cancer Net-
work Clinical Practice Guidelines in Oncology, which both 
recommend that moderate or severe pain should prompt a 
clinical response [15, 16]. The SUPPORT study (Study to 
Understand Prognoses and Preferences for Outcomes and 
Risks of Treatments) also used this classification to cat-
egorize reports of pain at the end of life [17]. Symptoms 
of depression were measured using the eight-item Center 
for Epidemiologic Studies Depression Scale [18, 19]. Par-
ticipants were classified as having symptoms consistent 
with the diagnosis of depression if they reported more 
than three symptoms.
The same nine patient-reported measures were also 
assessed at the first HRS interview after a diagnosis of 
multiple myeloma.
Statistical analysis
We started with describing the multiple myeloma patients 
in terms of demographics, socioeconomic status and health 
status. Next, we assessed the frequency of each patient-
reported measure before a multiple myeloma diagnosis. 
Depression was not assessed for participants with proxy 
respondents; therefore, 10 patients were not included 
in the analysis of frequency and changes in depression. 
Questions about pain levels was not asked in early HRS 
interviews (1992–1993), so 5 patients were not included 
in the analyses invlolving significant pain. Analyses were 
conducted independently for each variable to prevent miss-
ing values from one variable affecting the sample size in 
the analysis of other variables.
Next, we compared the frequency of adverse health on 
the patient-reported measures before and after a multiple 
myeloma diagnosis. Only patients that completed the inter-
view after their multiple myeloma diagnosis were included 
in this analysis, as the goal of this study was to describe 
well-being and changes in well-being of the patients who 
survive the initial period after multiple myeloma diagno-
sis. Patients who died within 2 years of multiple myeloma 
diagnosis, but completed an HRS interview between their 
diagnosis and death, were included in the study. The com-
parison of patients before and after multiple myeloma 
diagnosis was done using McNemar’s test.
Finally, we compared the change in frequency of 
adverse health on the patient-reported measures between 
HRS patients with a diagnosis of multiple myeloma to 
those without the diagnosis over the same time period, 
i.e., selecting subjects interviewed around the same time. 
To perform this comparison, we matched each patient 
with multiple myeloma to five individuals without mul-
tiple myeloma. The matching was performed using a 
mixture of propensity score matching and exact match-
ing. Patients were matched on propensity score for being 
diagnosed with multiple myeloma, calculated using age, 
gender, race, marital status, education, wealth, number of 
comorbidities, and smoking status. Additionally, patients 
were matched on exact year of interview before and after 
a diagnosis of multiple myeloma, and on exact status of 
patient-reported measure for the multiple myeloma patient 
before the diagnosis. The matching was done separately 
for each patient-reported measure. This analysis was again 
limited only those patients who completed the HRS inter-
view after a diagnosis of multiple myeloma, as our goal 
was to describe the experience among surviving patients.
Statistical analyses were performed using SAS 9.4 [20] 
and R 3.4 [21, 22] software. This study has been approved 
by the Center for Disease Control’s Institutional Review 
Board (CDC).
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Results
Table 1 describes the prediagnosis baseline characteristics 
of the multiple myeloma patients included in this study. 
The mean age of 92 patients was 74.6 (SD = 8.4), and 47% 
were women. Forty-three percent of patients had 3 or more 
chronic conditions before diagnosis. The most common 
ADL difficulties were getting dressed (13%) and bathing 
(13%). The most common IADL difficulties shopping for 
groceries (17%) and preparing hot meals (17%). Eighteen 
patients (20%) died within 1 year, and 38 (41%) died within 
2 years of multiple myeloma diagnosis. This mortality rate 
is comparable to mortality rates reported in other long-term 
studies of older adults [2, 23]. Of the 92 patients included 
in the study, 66 (72%) completed HRS interview after mul-
tiple myeloma diagnosis. Most subjects not completing an 
interview died before there scheduled interview. The median 
time between interview before multiple myeloma diagnosis 
and the diagnosis was 13.0 months (IQR 6.3–19.1), and the 
median time between the diagnosis and the first interview 
after the diagnosis was 12.6 months (6.0–18.0) (Table 1).
About a quarter of all multiple myeloma patients reported 
difficulty with at least one ADL (n = 22, 24%) before the 
diagnosis (Table 2). Twenty-nine patients (32%) reported 
difficulty with at least one IADL, 34 patients (37%) reported 
difficulty with walking several blocks, and 25 patients (27%) 
reported difficulty with climbing one flight of stairs. Vision 
impairment was reported by 29 patients (32%), and hear-
ing impairment was reported by 20 patients (22%) before 
multiple myeloma diagnosis. About a quarter of the patients 
experienced significant pain (n = 20, 23%), and about a fifth 
reported symptoms of depression (n = 15, 19%). The most 
common impairment before multiple myeloma diagnosis 
was poor or fair self-reported health (n = 37, 40%).
Impairments in patient-reported measures in surviving 
multiple myeloma patients increased significantly after the 
diagnosis (Table 3). Patients reported higher rates of dif-
ficulty in three of the four physical measures, including 
increases in ADL difficulty (23% to 40%, p = 0.02), difficulty 
walking several blocks (30% to 60%, p < 0.001), and diffi-
culty climbing one flight of stairs (25% to 47%, p = 0.003). 
There was no statistically significant change in IADL dif-
ficulty (30% to 41%, p = 0.13) The rate of depression symp-
toms doubled after the diagnosis (15% to 30%, p = 0.02), and 
Table 1  Baseline characteristics of multiple myeloma patients before 
diagnosis
BMI body mass index, ADL activities of daily living, IADL instru-
mental activities of daily living
Characteristics N (%)
Age 74.6 ± 8.4
Women 43 (47%)
White race 70 (76%)
Married 54 (59%)
Education less than High School 25 (27%)
Wealth (median, IQR) 151 K (45–405 K)
BMI
 ≤ 25 31 (34%)
 > 25 59 (66%)
Number of comorbidities ≥ 3 40 (43%)
Previous diagnosis of cancer 27 (30%)





 Walking across the room 9 (10%)
 Transferring to and from bed 8 (9%)
 Dressing 12 (13%)
 Using toilet 6 (7%)
IADL difficulty
 Using the telephone 6 (7%)
 Managing finances 13 (14%)
 Managing medications 6 (7%)
 Shopping for groceries 15 (17%)
 Preparing meals 15 (17%)
Proxy interview 10 (11%)
Months between interview before diagnosis and 
diagnosis (median, IQR)
13.0 (6.3–19.1)
Months between diagnosis and interview after 
diagnosis (median, IQR)
12.6 (6.0–18.0)
Died within 1 year of diagnosis 18 (20%)
Died within 2 years of diagnosis 38 (41%)
Table 2  Frequency of impairment on patient reported measures in the 
interview before multiple myeloma diagnosis
a Number of missing values for each variable is as follows: Difficulty 
was any ADL (1). Difficulty with any IADL (2), Difficulty with walk-
ing several blocks (1), Difficulty with climbing one flight of stairs (1), 
Significant pain (6), Depression (11)
Characteristic N (%)a
Physical impairment
 Difficulty with any ADL 22 (24%)
 Difficulty with any IADL 29 (32%)
 Difficulty with walking several blocks 34 (37%)
 Difficulty with climbing one flights of stairs 25 (27%)
Sensory impairment
 Vision Impairment 29 (32%)
 Hearing Impairment 20 (22%)
Patient experience
 Significant pain 20 (23%)
 Poor self-rated health 37 (40%)
 Depression 15 (19%)
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more patients reported poor or fair self-rated health (38% to 
61%, p = 0.004). There was no significant increase in patients 
experiencing significant pain (27% to 38%, p = 0.09). There 
was no change at all in the rates of vision impairment (30% 
to 30%, p = 1), but patients reported significant increase in 
hearing impairment (20% to 33%, p = 0.04).
Matched HRS participants without a multiple myeloma 
diagnosis reported lower rates of some patient-reported 
measures in the interview after the multiple myeloma 
diagnosis of the patients (Table 4), even though they were 
matched to have the same level of impairment before the 
diagnosis. Participants without multiple myeloma reported 
lower rates in ADL difficulty (40% vs. 27%, p = 0.04), dif-
ficulty walking several blocks (60% vs. 37%, p < 0.001), 
and difficulty climbing one flight of stairs (47% vs. 29%, 
p = 0.005). There were no statistically significant differences 
in IADL difficulty (41% vs. 32%, p = 0.21), vision impair-
ment (30% vs. 26%, p = 0.52), or hearing impairment (33% 
vs. 29%, p = 0.44). Multiple myeloma patients reported 
higher rates of poor or fair self-rated health (61% vs. 39%, 
p = 0.001), depression symptoms (29% vs. 11%, p = 0.003), 
and significant pain (38% vs. 22%, p = 0.01).
Table 3  Frequency of 
impairment on patient-reported 
measures in the interviews 
before and after multiple 
myeloma (MM) diagnosis, in 
patients who survived until 
HRS interview after diagnosis




After MM diagnosis p value
Physical impairment
 Difficulty with any ADL 65 15 (23%) 26 (40%) 0.016
 Difficulty with any IADL 64 19 (30%) 26 (41%) 0.127
 Difficulty with walking several blocks 63 19 (30%) 38 (60%) <0.001
 Difficulty with climbing one flights of stairs 59 15 (25%) 28 (47%) 0.003
Sensory impairment
 Vision impairment 66 20 (30%) 20 (30%) 1.000
 Hearing impairment 66 13 (20%) 22 (33%) 0.039
Patient experience
 Significant pain 64 17 (27%) 24 (38%) 0.090
 Poor self-rated health 64 24 (38%) 39 (61%) 0.004
 Depression 53 8 (15%) 16 (30%) 0.021
Table 4  Change in impairment 
of patient-reported measures 
in surviving multiple myeloma 
(MM) patients and HRS 
participants without multiple 
myeloma
a Each multiple myeloma patient was matched to 5 HRS participants without multiple myeloma diagnosis 
based on age, gender, race/ethnicity, marital status, education, wealth, number of comorbidities, and smok-
ing status (using propensity score for multiple myeloma diagnosis) and exact matching on year of interview 
before and after diagnosis, and the presence of each patient-reported measures of interest at the interview 












 Difficulty with any ADL 15 (23%) 26 (40%) 87 (27%) 0.04
 Difficulty with any IADL 19 (30%) 26 (41%) 95 (32%) 0.21
 Difficulty with walking several blocks 19 (30%) 38 (60%) 119 (37%) < 0.001
 Difficulty with climbing one flights of stairs 15 (25%) 28 (47%) 91 (29%) 0.005
Sensory impairment
 Vision impairment 20 (30%) 20 (30%) 87 (26%) 0.52
 Hearing impairment 13 (20%) 22 (33%) 94 (29%) 0.44
Patient experience
 Significant pain 17 (27%) 24 (38%) 69 (22%) 0.01
 Poor self-rated health 24 (38%) 39 (61%) 128 (39%) 0.001
 Depression 6 (13%) 14 (29%) 17 (11%) 0.003
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Discussion
Using Medicare claims data linked to 26,044 HRS sub-
jects, we identified 105 patients with multiple myeloma, 
92 of which completed HRS interviews within 3 years 
of diagnosis. Our study showed that a multiple myeloma 
diagnosis negatively affects several aspects of patients’ 
well-being. Decline in several, but not all, patient-reported 
measures was significantly larger among surviving multi-
ple myeloma patients than the changes among similar par-
ticipants without multiple myeloma diagnosis. These find-
ings have a number of limitations imposed by the nature of 
the HRS data, yet also provide new insights beyond what 
is possible with primary data collection.
Health and Retirement Study was not collected for 
the purpose of learning about multiple myeloma, yet the 
design and richness of HRS study makes it possible to 
describe important aspects of the patient experience. 
While the multiple myeloma sample in our study is not 
a large sample that allows for multivariate modeling, it 
is large enough for exploratory analyses and meaning-
ful description of changes in impairments that matter to 
patients before and after diagnosis of multiple myeloma. 
We obtained this sample using significantly less resources 
and time than would be required to recruit the same num-
ber of multiple myeloma patients. For example, a pri-
mary data collection study that lasted from 2012 to 2015 
recruited only 40 older patients [5], while another study 
recruited 41 adult patients of all ages in 3 months [4]. 
Furthermore, by leveraging the longitudinal nature of the 
HRS, our study was able to obtain data on patient-reported 
measures of interest prior to diagnosis, which would be 
impossible to obtain using primary data collection. Our 
study shows that we can use alternative data sources, such 
as claims data or larger observational studies, to design 
and perform some basic, but important, health research 
studies on rare diseases.
Our study indicates significant decline in several 
patient-reported measures in multiple myeloma patients 
after diagnosis. First, our study shows that surviving 
patients experience significant functional decline after the 
diagnosis, as measured by difficulty with activities of daily 
living and mobility. Prior studies in older patients with 
other types of cancer have also shown the functional status 
declines after cancer diagnoses [24, 25]. While decline in 
those domains is common in ageing persons, we have also 
shown that the functional decline in multiple myeloma 
patients is significantly higher than decline in similar HRS 
participants without multiple myeloma diagnosis. Our 
study also shows that there is significant decline in patient 
well-being, as assessed by pain, self-reported health, and 
depression. Similar to functional decline, reports of pain, 
poor or fair self-rated health, and depressive symptoms 
become more common in surviving multiple myeloma 
patients after diagnosis than participants without multi-
ple myeloma. These results are analogous to results of 
another study based on secondary longitudinal data source 
(English Longitudinal Study of Ageing), which showed 
that health and well-being of patient with cancer of any 
type deteriorated more rapidly than health and well-being 
of similar patient without cancer diagnosis [26]. Our find-
ings are significant, since impairments in well-being can 
themselves lead to further bad outcomes in older patients 
[4, 27, 28].
The measures of function and well-being that we consid-
ered in this study are rarely targets of therapy in older per-
sons with cancer and seldom used as outcome measures in 
clinical trials of treatments for myeloma and other cancers. 
Yet these measures are very important to cancer patients, 
some of whom view quality of life as a more important 
outcome than survival. The use of population-based data 
sources such as the HRS to determine which measures of 
function and well-being are mostly likely to deteriorate after 
a cancer diagnosis may be useful in helping designers of 
cancer treatment trials consider the types of outcome meas-
ures that might be included in their trials. Furthermore, both 
the high mortality rate of multiple myeloma patients (20% 
1-year mortality) and the high likelihood of worsening qual-
ity of life in patients with multiple myeloma highlights the 
importance of holistic assessment and appropriate geriatric 
and palliative care. Palliative care has been recognized as 
an important part of care for cancer patients [29, 30], where 
patients’ physical, mental, and psychosocial needs need to 
be addressed in addition to treating the underlying cancer. 
Unfortunately, a prior study has shown that patients with 
hematological cancers are less likely to receive palliative 
care than patients with other cancers [31].
It is important to discuss several issues in this study that 
can limit the clinical conclusions of this and other studies 
using this type of secondary data. First, the time between 
multiple myeloma diagnosis and the interview before the 
diagnosis varies from 8 days to 34 months. Since patient-
reported measures are not always measured immediately 
before the diagnosis, patient-reported measures might have 
changed for some patients between the last measurement and 
multiple myeloma diagnosis. Similarly, the time between 
the diagnosis and the interview after the diagnosis also 
varies. The patient-reported measures are likely to change 
often as the treatments progress, including repeated periods 
of improvement and decline [6]. Second, we do not have 
information on the treatments that each patient is receiving, 
which prevents us from understanding how different treat-
ments affect the outcomes, and when in the treatment cycle 
the changes occur. Thus, our results further highlight the 
importance of including this important information about 
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patient oriented outcomes in observational and clinical stud-
ies of cancer therapeutics.
Our study showed that secondary data can be used to 
identify patients with rare diseases, and perform exploratory 
and hypotheses generating studies. We showed that patient-
reported measures in older adults worsen after multiple 
myeloma diagnosis, and the decline in surviving multiple 
myeloma patients is significantly worse than the decline is 
similar older adults without multiple myeloma. This indi-
cates that older patients could benefit from supportive geri-
atric and palliative care to help manage the symptoms that 
worsen with multiple myeloma diagnosis and treatment.
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